AI Article Synopsis
- The study aims to demonstrate how adalimumab (ADA) can reduce the reliance on steroids in treating the chronic recurrent phase of Vogt-Koyanagi-Harada (VKH) disease.
- A total of 36 eyes from 18 patients were examined, with some previously treated with prednisolone (PSL) alone or in combination with cyclosporine A (CYA) before switching to ADA.
- Results showed a significant reduction in the minimum dose of PSL required to manage inflammation after starting ADA, confirming its steroid-sparing effect without serious side effects noted.
Article Abstract
Purpose: To reveal the steroid-sparing effect of adalimumab (ADA) in the treatment for the chronic recurrent phase of Vogt-Koyanagi-Harada (VKH) disease.
Cases And Methods: Thirty-six eyes from 18 cases of the recurrent phase of VKH disease treated with ADA over 12 months were examined retrospectively. Before the introduction of ADA, 4 cases received prednisolone (PSL) monotherapy and other 14 cases received PSL and cyclosporine A (CYA) combination therapy.
Results: In cases treated with PSL and CYA, CYA was discontinued when ADA was introduced. The minimum dose of PSL to control intraocular inflammation (min dose of PSL) could be reduced in all cases after the introduction of ADA (from 16.9 ± 7.9 mg to 6.3 ± 3.1 mg). No serious adverse events were observed in the observational periods.
Conclusion: By comparing the min dose of PSL before and after the introduction of ADA, the steroid-sparing effect of ADA was confirmed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2022.2037657 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!